Evidence map›Paper›PMID 33148622›Full record

ArticleScience translational medicine2020

Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice.

Giacomo Casella, Javad Rasouli, Alexandra Boehm, Weifeng Zhang, Dan Xiao, Larissa Lumi Watanabe Ishikawa, Rodolfo Thome, Xing Li, Daniel Hwang, Patrizia Porazzi and 5 more

Open access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 98 citations in OpenAlex.

  1. Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Giacomo CasellaDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-1103-6303
Javad RasouliDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-0276-873X
Alexandra BoehmDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Weifeng ZhangDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-6176-4907
Dan XiaoDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Larissa Lumi Watanabe IshikawaDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0003-3481-2181
Rodolfo ThomeDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0001-7627-4137
Xing LiNational Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest China, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.ORCID 0000-0002-0742-1364
Daniel HwangDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0002-6071-8271
Patrizia PorazziSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Sudheer MoluguDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-9939-1950
Hsin-Yao TangProteomics and Metabolomics Facility, Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0003-1838-018X
Guang-Xian ZhangDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0003-0017-5997
Bogoljub CiricDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA.ORCID 0000-0001-5361-7635
Abdolmohamad RostamiDepartment of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA. a.m.rostami@jefferson.edu.ORCID 0000-0003-0716-2726
Thomas Jefferson University · USShaanxi Normal University · CNThe Wistar Institute · USUniversity of Pennsylvania · US

Funding

Advancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1M
Mechanisms of GM-CSF effect in CNS autoimmune demyelinationR01AI124386 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ROSTAMI, A.M. · 2017 to 2021
$1.9M
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunityR01AI152251 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ROSTAMI, A.M. · 2020 to 2025
$1.9M
The role of IL-27 in iv tolerance in EAER01AI106026 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI ROSTAMI, A.M. · 2014 to 2018
$1.9M
NCI NIH HHS R50 CA221838NIAID NIH HHS R01 AI106026NIAID NIH HHS R01 AI124386NIAID NIH HHS R01 AI152251
6 · The paper itself

Abstract

Autoimmune diseases such as multiple sclerosis (MS) develop because of failed peripheral immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific suppression of autoimmune neuroinflammation have been proven effective in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. One such approach is intravenous tolerance induction by injecting a myelin Ag used for triggering EAE. However, the translation of this and similar experimental strategies into therapy for MS has been hampered by uncertainty regarding relevant myelin Ags in MS patients. To address this issue, we developed a therapeutic strategy that relies on oligodendrocyte (Ol)-derived extracellular vesicles (Ol-EVs), which naturally contain multiple myelin Ags. Intravenous Ol-EV injection reduced disease pathophysiology in a myelin Ag-dependent manner, both prophylactically and therapeutically, in several EAE models. The treatment was safe and restored immune tolerance by inducing immunosuppressive monocytes and apoptosis of autoreactive CD4

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalExtracellular VesiclesMultiple SclerosisAnimalsHumansMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinOligodendrogliaMyelin-Oligodendrocyte Glycoprotein

Identifiers

PMID33148622
PMCPMC7886371
OpenAlexW3095932988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.